Search

Your search keyword '"Ariane Vieira Scarlatelli Macedo"' showing total 12 results
Start Over Author "Ariane Vieira Scarlatelli Macedo" Publication Year Range Last 3 years
12 results on '"Ariane Vieira Scarlatelli Macedo"'

1. Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP)

Author

Fábio Fernandes, Georgina del Cisne Jadán Luzuriaga, Guilherme Wesley Peixoto da Fonseca, Edileide Barros Correia, Alzira Alves Siqueira Carvalho, Ariane Vieira Scarlatelli Macedo, Otavio Rizzi Coelho-Filho, Phillip Scheinberg, Murillo Oliveira Antunes, Pedro Vellosa Schwartzmann, Sandrigo Mangini, Wilson Marques, and Marcus Vinicius Simões

Subjects
Cardiac Amyloidosis, Epidemiology, Polyneuropathy, Registry, Transthyretin Amyloidosis, Medicine
Abstract

Abstract Background Transthyretin amyloidosis (ATTR) is a multisystem disease caused by the deposition of fibrillar protein in organs and tissues. ATTR genotypes and phenotypes are highly heterogeneous. We present data on physical signs and symptoms, cardiac and neurological assessments and genetic profile of patients enrolled in the Transthyretin Cardiac Amyloidosis Registry of the State of São Paulo, Brazil. Results Six hundred-forty-four patients were enrolled, 505 with the variant form (ATTRv) and 139 with wild-type (ATTRwt). Eleven different mutations were detected, the most common being Val50Met (47.5%) and V142Ile (39.2%). Overall, more than half of the patients presented cardiac involvement, and the difference in this proportion between the ATTRv and ATTRwt groups was significant (43.9 vs. 89.9%; p

Published
2024
Full Text
View/download PDF

2. Diretriz sobre Diagnóstico e Tratamento da Cardiomiopatia Hipertrófica – 2024

Author

Fabio Fernandes, Marcus V. Simões, Edileide de Barros Correia, Fabiana Goulart Marcondes-Braga, Otavio Rizzi Coelho-Filho, Cláudio Tinoco Mesquita, Wilson Mathias Junior, Murillo de Oliveira Antunes, Edmundo Arteaga-Fernández, Carlos Eduardo Rochitte, Felix José Alvarez Ramires, Silvia Marinho Martins Alves, Marcelo Westerlund Montera, Renato Delascio Lopes, Mucio Tavares de Oliveira Junior, Fernando Luis Scolari, Walkiria Samuel Avila, Manoel Fernandes Canesin, Edimar Alcides Bocchi, Fernando Bacal, Lidia Zytynski Moura, Eduardo Benchimol Saad, Mauricio Ibrahim Scanavacca, Bruno Pereira Valdigem, Manuel Nicolas Cano, Alexandre Antonio Cunha Abizaid, Henrique Barbosa Ribeiro, Pedro Alves Lemos Neto, Gustavo Calado de Aguiar Ribeiro, Fabio Biscegli Jatene, Ricardo Ribeiro Dias, Luis Beck-da-Silva, Luis Eduardo Paim Rohde, Marcelo Imbroinise Bittencourt, Alexandre da Costa Pereira, José Eduardo Krieger, Humberto Villacorta Junior, Wolney de Andrade Martins, José Albuquerque de Figueiredo Neto, Juliano Novaes Cardoso, Carlos Alberto Pastore, Ieda Biscegli Jatene, Ana Cristina Sayuri Tanaka, Viviane Tiemi Hotta, Minna Moreira Dias Romano, Denilson Campos de Albuquerque, Ricardo Mourilhe-Rocha, Ludhmila Abrahão Hajjar, Fabio Sandoli de Brito Junior, Bruno Caramelli, Daniela Calderaro, Pedro Silvio Farsky, Alexandre Siciliano Colafranceschi, Ibraim Masciarelli Francisco Pinto, Marcelo Luiz Campos Vieira, Luiz Claudio Danzmann, Silvio Henrique Barberato, Charles Mady, Martino Martinelli Filho, Ana Flavia Malheiros Torbey, Pedro Vellosa Schwartzmann, Ariane Vieira Scarlatelli Macedo, Silvia Moreira Ayub Ferreira, Andre Schmidt, Marcelo Dantas Tavares de Melo, Moysés Oliveira Lima Filho, Andrei C. Sposito, Flávio de Souza Brito, Andreia Biolo, Vagner Madrini Junior, Stephanie Itala Rizk, and Evandro Tinoco Mesquita

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Published
2024
Full Text
View/download PDF

3. Posicionamento sobre Doença Isquêmica do Coração – A Mulher no Centro do Cuidado – 2023

Author

Gláucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Daniela do Carmo Rassi, Érika Olivier Vilela Bragança, Lidia Zytynski Moura, Magaly Arrais, Milena dos Santos Barros Campos, Viviana Guzzo Lemke, Walkiria Samuel Avila, Alexandre Jorge Gomes de Lucena, André Luiz Cerqueira de Almeida, Andréa Araujo Brandão, Andrea Dumsch de Aragon Ferreira, Andreia Biolo, Ariane Vieira Scarlatelli Macedo, Breno de Alencar Araripe Falcão, Carisi Anne Polanczyk, Carla Janice Baister Lantieri, Celi Marques-Santos, Claudia Maria Vilas Freire, Denise Pellegrini, Elizabeth Regina Giunco Alexandre, Fabiana Goulart Marcondes Braga, Fabiana Michelle Feitosa de Oliveira, Fatima Dumas Cintra, Isabela Bispo Santos da Silva Costa, José Sérgio Nascimento Silva, Lara Terra F. Carreira, Lucelia Batista Neves Cunha Magalhães, Luciana Diniz Nagem Janot de Matos, Marcelo Heitor Vieira Assad, Marcia M. Barbosa, Marconi Gomes da Silva, Maria Alayde Mendonça Rivera, Maria Cristina de Oliveira Izar, Maria Elizabeth Navegantes Caetano Costa, Maria Sanali Moura de Oliveira Paiva, Marildes Luiza de Castro, Marly Uellendahl, Mucio Tavares de Oliveira Junior, Olga Ferreira de Souza, Ricardo Alves da Costa, Ricardo Quental Coutinho, Sheyla Cristina Tonheiro Ferro da Silva, Sílvia Marinho Martins, Simone Cristina Soares Brandão, Susimeire Buglia, Tatiana Maia Jorge de Ulhôa Barbosa, Thais Aguiar do Nascimento, Thais Vieira, Valquíria Pelisser Campagnucci, and Antonio Carlos Palandri Chagas

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Published
2023
Full Text
View/download PDF

4. Posicionamento sobre a Saúde Cardiovascular nas Mulheres – 2022

Author

Glaucia Maria Moraes de Oliveira, Maria Cristina Costa de Almeida, Celi Marques-Santos, Maria Elizabeth Navegantes Caetano Costa, Regina Coeli Marques de Carvalho, Cláudia Maria Vilas Freire, Lucelia Batista Neves Cunha Magalhães, Ludhmila Abrahão Hajjar, Maria Alayde Mendonça Rivera, Marildes Luiza de Castro, Walkiria Samuel Avila, Alexandre Jorge Gomes de Lucena, Andréa Araujo Brandão, Ariane Vieira Scarlatelli Macedo, Carla Janice Baister Lantieri, Carisi Anne Polanczyk, Carlos Japhet da Matta Albuquerque, Daniel Born, Eduardo Belisário Falcheto, Érika Olivier Vilela Bragança, Fabiana Goulart Marcondes Braga, Fernanda M. Consolim Colombo, Ieda Biscegli Jatene, Isabela Bispo Santos da Silva Costa, Ivan Romero Rivera, Jaqueline Ribeiro Scholz, José Xavier de Melo Filho, Magaly Arrais dos Santos, Maria Cristina de Oliveira Izar, Maria Fátima Azevedo, Maria Sanali Moura, Milena dos Santos Barros Campos, Olga Ferreira de Souza, Orlando Otávio de Medeiros, Sheyla Cristina Tonheiro Ferro da Silva, Stéphanie Itala Rizk, Thais de Carvalho Vieira Rodrigues, Thaís Rocha Salim, and Viviana de Mello Guzzo Lemke

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Published
2022
Full Text
View/download PDF

5. Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial

Author

André Luiz Malavasi Longo de Oliveira MD, MSc, Renata Fernanda de Oliveira Pereira MD, Leandro Barile Agati Ph.D, Camilla Moreira Ribeiro Ph.D, Gabrielly Yukimi Kawamura Suguiura, Claudia Helena Cioni MD, Marilsa Bermudez MD, Márcia Bermudez Pirani MD, Roberto Augusto Caffaro MD, Ph.D, Valter Castelli, Valéria Cristina Resende Aguiar MD, Giuliano Giova Volpiani MD, Adilson Paschoa MD, Ph.D, Ariane Vieira Scarlatelli Macedo MD, Pedro Gabriel Melo de Barros e Silva MD, Ph.D, João Carlos de Campos Guerra MD, Ph.D, Jawed Fareed Ph.D, Renato Delascio Lopes MD, Ph.D, and Eduardo Ramacciotti MD, Ph.D

Subjects
Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) prevention after major gynecological cancer surgery might be an alternative to parenteral low-molecular-weight heparin (LMWH). Patients undergoing major gynecological cancer surgery were randomized at hospital discharge to receive rivaroxaban 10 mg once daily or enoxaparin 40 mg once daily for 30 days. The primary efficacy outcome was a combination of symptomatic VTE and VTE-related death or asymptomatic VTE at day 30. The primary safety outcome was the incidence of major or clinically relevant nonmajor bleeding. Two hundred and twenty-eight patients were enrolled and randomly assigned to receive rivaroxaban (n = 114)or enoxaparin (n = 114). The trial was stopped due to a lower-than-expected event rate. The primary efficacy outcome occurred in 3.51% of patients assigned to rivaroxaban and in 4.39% of patients assigned to enoxaparin (relative risk 0.80, 95% CI 0.22 to 2.90; p = 0.7344). Patients assigned to rivaroxaban had no primary bleeding event, and 3 patients (2.63%) in the enoxaparin group had a major or CRNM bleeding event (hazard ratio, 0.14; 95% CI, 0.007 to 2.73; P = 0.1963). In patients undergoing major gynecological cancer surgery, thromboprophylaxis with rivaroxaban 10 mg daily for 30 days had similar rates of thrombotic and bleeding events compared to parenteral enoxaparin 40 mg daily. While the power is limited due to not reaching the intended sample size, our results support the hypothesis that DOACs might be an attractive alternative strategy to LMWH to prevent VTE in this high-risk population.

Published
2022
Full Text
View/download PDF

7. Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial

Author

Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros e Silva, Thiago Ceccatto de Paula, Renata Junqueira Moll-Bernardes, Tiago Mendonça dos Santos, Lilian Mazza, Andre Feldman, Guilherme D`Andréa Saba Arruda, Denílson Campos de Albuquerque, Andrea Silvestre de Sousa, Olga Ferreira de Souza, C. Michael Gibson, Christopher B. Granger, John H. Alexander, and Renato D. Lopes

Subjects
Angiotensin Receptor Antagonists, SARS-CoV-2, Hypertension, COVID-19, Humans, Angiotensin-Converting Enzyme Inhibitors, Cardiology and Cardiovascular Medicine, Severity of Illness Index
Abstract

We explored the effect of discontinuing versus continuing angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on clinical outcomes in patients with COVID-19 according to baseline disease severity.We randomized 659 patients with a confirmed diagnosis of COVID-19 and classified them as having mild or moderate COVID-19 disease severity at hospital presentation using blood oxygen saturation and lung imaging. The primary outcome was the mean ratio of number of days alive and out of the hospital at 30 days according to disease severity.At presentation, 376 patients (57.1%) had mild and 283 (42.9%) had moderate COVID-19. In patients with mild disease, there was no significant difference in the number of days alive and out of the hospital between ACEI/ARB discontinuation (mean 23.5 [SD 6.3] days) and continuation (mean 23.8 [SD 6.5] days), with a mean ratio of 0.98 (95% CI 0.92-1.04). However, in patients with moderate disease, there were fewer days alive and out of the hospital with ACEI/ARB discontinuation (mean 19.6 [SD 9.5] days) than continuation (mean 21.6 [SD 7.6] days), with a mean ratio of 0.90 (95% CI 0.81-1.00; P-interaction = .01). The impact of discontinuing versus continuing ACEIs/ARBs on days alive and out of hospital through 30 days differed according to baseline COVID-19 disease severity.Unlike patients with mild disease, patients with moderate disease who continued ACEIs/ARBs had more days alive and out of hospital through 30 days than those who discontinued ACEIs/ARBs. This suggests that ACEIs/ARBs should be continued for patients with moderate COVID-19 disease severity.ClinicalTrials.gov (NCT04364893).

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results